EXCALIBER-RRMM: A PHASE 3, TWO-STAGE STUDY OF IBERDOMIDE, DARATUMUMAB, AND DEXAMETHASONE VERSUS DARATUMUMAB, BORTEZOMIB, AND DEXAMETHASONE IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA

EHA Library, Sagar Lonial, 387240

IMPACT OF TRANSFUSION BURDEN ON HEALTH-RELATED QUALITY OF LIFE AND FUNCTIONING IN PATIENTS WITH MYELOFIBROSIS: POST HOC ANALYSIS OF SIMPLIFY-1 AND -2

EHA Library, Ruben Mesa, 387290

FIVE-YEAR SUBGROUP ANALYSIS OF TAFASITAMAB + LENALIDOMIDE FROM THE PHASE II L-MIND STUDY IN PATIENTS WITH RELAPSED OR REFRACTORY DIFFUSE LARGE B-CELL LYMPHOMA

EHA Library, Johannes Duell, 387406

LUSPATERCEPT VERSUS EPOETIN ALFA FOR TREATMENT (TX) OF ANEMIA IN ESA-NAIVE LOWER-RISK MYELODYSPLASTIC SYNDROMES (LR-MDS) PATIENTS (PTS) REQUIRING RBC TRANSFUSIONS: DATA FROM THE PHASE 3 COMMANDS STUDY

EHA Library, Matteo Giovanni Della Porta, 387802

EFFICACY AND SAFETY OF LUSPATERCEPT FOR THE TREATMENT OF ANEMIA IN PATIENTS WITH MYELOFIBROSIS: RESULTS FROM THE ACE-536-MF-001 STUDY

EHA Library, Francesco Passamonti, 387867

PELABRESIB (CPI-0610) MONOTHERAPY IN PATIENTS WITH HIGH-RISK ESSENTIAL THROMBOCYTHEMIA REFRACTORY OR INTOLERANT TO HYDROXYUREA: PRELIMINARY RESULTS FROM MANIFEST STUDY

EHA Library, Francesco Passamonti, 387868

A PHASE 3, OPEN-LABEL, RANDOMIZED STUDY EVALUATING THE EFFICACY AND SAFETY OF SINGLE AGENT BELANTAMAB MAFODOTIN VS POMALIDOMIDE PLUS DEXAMETHASONE IN RELAPSED/REFRACTORY MULTIPLE MYELOMA (DREAMM-3)

EHA Library, Meletios Dimopoulos, 387899

HIGH COMPLETE RESPONSE RATE WITH TNB-486, A NOVEL CD19XCD3 T-CELL ENGAGER, IN RELAPSED/REFRACTORY FOLLICULAR LYMPHOMA: INTERIM RESULTS FROM AN ONGOING PHASE 1 STUDY

EHA Library, Ryan Jacobs, 387924

RESULTS OF A PHASE 3 TRIAL OF AN ORAL CXCR4 ANTAGONIST, MAVORIXAFOR, FOR TREATMENT OF PATIENTS WITH WHIM SYNDROME

EHA Library, Jean Donadieu, 387880

SPLEEN VOLUME REDUCTION PREDICTS SURVIVAL IN MYELOFIBROSIS PATIENTS ON PACRITINIB BUT NOT BEST AVAILABLE THERAPY: PERSIST-2 LANDMARK OVERALL SURVIVAL ANALYSIS

EHA Library, Jan Bewersdorf, 385480

CONSISTENCY OF PACRITINIB FOR SPLEEN AND SYMPTOM REDUCTION IN PATIENTS WITH MYELOFIBROSIS REGARDLESS OF CYTOPENIAS

EHA Library, Nico Gagelmann, 385487

LONG-TERM REMISSION AND SURVIVAL IN PATIENTS WITH RELAPSED OR REFRACTORY MULTIPLE MYELOMA AFTER TREATMENT OF LCAR-B38M CAR-T – AT LEAST 5-YEAR FOLLOW-UP IN LEGEND-2

EHA Library, Jian‑Qing Mi, 386703

LONG-TERM FOLLOW-UP FROM MAJESTEC-1 OF TECLISTAMAB, A B-CELL MATURATION ANTIGEN (BCMA) X CD3 BISPECIFIC ANTIBODY, IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA (RRMM)

EHA Library, Surbhi Sidana, 386708

DURABILITY OF RESPONSES WITH BIWEEKLY DOSING OF TECLISTAMAB IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA ACHIEVING A CLINICAL RESPONSE IN THE MAJESTEC-1 STUDY

EHA Library, Manisha Bhutani, 386710

ANALYSIS OF INFECTIONS AND PARAMETERS OF HUMORAL IMMUNITY IN PATIENTS (PTS) WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA (RRMM) TREATED WITH TALQUETAMAB (TAL) MONOTHERAPY IN MONUMENTAL-1

EHA Library, Leo Rasche, 386721

EVALUATION OF PROPHYLACTIC TOCILIZUMAB (TOCI) FOR THE REDUCTION OF CYTOKINE RELEASE SYNDROME (CRS) TO INFORM THE MANAGEMENT OF PATIENTS (PTS) TREATED WITH TECLISTAMAB IN MAJESTEC-1

EHA Library, Niels W.C.J. van de Donk, 386740

PATIENT PERSPECTIVES ON BCMA-TARGETED THERAPIES FOR MULTIPLE MYELOMA: A SURVEY CONDUCTED IN A PATIENT ADVOCACY GROUP

EHA Library, Jay R. Hydren, 386761

FIRST RESULTS FROM THE REDIRECTT-1 STUDY WITH TECLISTAMAB (TEC) + TALQUETAMAB (TAL) SIMULTANEOUSLY TARGETING BCMA AND GPRC5D IN PATIENTS (PTS) WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA (RRMM)

EHA Library, María-Victoria Mateos, 387890

PIVOTAL PHASE 2 MONUMENTAL-1 RESULTS OF TALQUETAMAB (TAL), A GPRC5DXCD3 BISPECIFIC ANTIBODY (BSAB), FOR RELAPSED/REFRACTORY MULTIPLE MYELOMA (RRMM)

EHA Library, Cyrille Touzeau, 387891

TALQUETAMAB (TAL) + DARATUMUMAB (DARA) IN PATIENTS (PTS) WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA (RRMM): UPDATED TRIMM-2 RESULTS

EHA Library, Nizar J Bahlis, 387892

CARTITUDE-1 FINAL RESULTS: PHASE 1B/2 STUDY OF CILTACABTAGENE AUTOLEUCEL IN HEAVILY PRETREATED PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA

EHA Library, Nikhil Munshi, 387902

Abstract Book 2023

EHA Library, Faculty / Presenters, 400189

FINAL 7-YEAR FOLLOW UP AND RETREATMENT SUBSTUDY ANALYSIS OF MURANO: VENETOCLAX-RITUXIMAB (VENR)-TREATED PATIENTS WITH RELAPSED/REFRACTORY CHRONIC LYMPHOCYTIC LEUKEMIA (R/R CLL)

EHA Library, Arnon P. Kater, 387901

QUADRUPLET INDUCTION THERAPY, ASCT AND MRD-MODULATED CONSOLIDATION AND TREATMENT CESSATION IN NEWLY DIAGNOSED MULTIPLE MYELOMA: FINAL ANALYSIS OF THE MASTER TRIAL

EHA Library, Luciano J. Costa, 387903

SAFETY AND TOLERABILITY OF CAEL-101, AN ANTI-AMYLOID MONOCLONAL ANTIBODY, COMBINED WITH ANTI-PLASMA CELL DYSCRASIA THERAPY IN PATIENTS WITH LIGHT-CHAIN AMYLOIDOSIS: 18-MONTH RESULTS OF A PHASE 2 STUDY

EHA Library, Jason Valent, 387904

INHIBITING THE ALARMIN-DRIVEN HEMATOPOIESIS-STROMAL CELLS CROSSTALK IN PRIMARY MYELOFIBROSIS AMELIORATES BONE MARROW FIBROSIS

EHA Library, Hélène Gleitz, 387905

ONCO-FETAL REPROGRAMMING DRIVES HIGH-RISK JUVENILE MYELOMONOCYTIC LEUKEMIA, WHICH CAN BE TARGETED BY ANTI-CD52 TREATMENT

EHA Library, Mark Hartmann, 387906

NAVTEMADLIN, AN ORAL MDM2 INHIBITOR, ELIMINATES MYELOPROLIFERATIVE NEOPLASM-BLAST PHASE (MPN-BP) INITIATING CELLS AND PROLONGS LEUKEMIA-FREE SURVIVAL (LFS) IN AN MPN-BP PDX MODEL

EHA Library, Xiaoli Wang, 387907

RELEVANCE OF DORMANT CANCER STEM CELLS IN DISEASE PROPAGATION AND THERAPY RESISTANCEIN JAK2V617F-DRIVEN MPN.

EHA Library, Ian Ghezzi, 387908

TARGETING THE SRC HOMOLOGY 2 DOMAIN-CONTAINING PHOSPHATASE SHP2 ENHANCES THE THERAPEUTIC EFFICACY OF JAK INHIBITION IN MYELOPROLIFERATIVE NEOPLASMS

EHA Library, Sarah Jungius, 387909

AN OPEN-LABEL, GLOBAL, PHASE (PH) 1B/2 STUDY ADDING NAVTEMADLIN (NVTM) TO RUXOLITINIB (RUX) IN PATIENTS (PTS) WITH PRIMARY OR SECONDARY MYELOFIBROSIS (MF) WHO HAVE A SUBOPTIMAL RESPONSE TO RUX

EHA Library, John Mascarenhas, 387910

EFFICACY AND SAFETY OF ROPEGINTERFERON ALFA-2B FOR PRE-FIBROTIC PRIMARY MYELOFIBROSIS AND DIPSS LOW/INTERMEDIATE-1 RISK MYELOFIBROSIS: UPDATED RESULTS AND GENOMIC CHARACTERISTICS

EHA Library, Harinder Gill, 387911

A RANDOMIZED DOUBLE-BLIND PHASE 3 STUDY OF JAKTINIB VERSUS HYDROXYUREA IN PATIENTS WITH INTERMEDIATE-2 OR HIGH RISK MYELOFIBROSIS

EHA Library, Yi Zhang, 387912

BMS-986158, A POTENT BET INHIBITOR, AS MONOTHERAPY AND IN COMBINATION WITH RUXOLITINIB OR FEDRATINIB IN INTERMEDIATE- OR HIGH-RISK MYELOFIBROSIS (MF): RESULTS FROM A PHASE 1/2 STUDY

EHA Library, Haifa Kathrin Al-Ali, 387913

DISEASE-MODIFYING ACTIVITY OF NAVTEMADLIN (NVTM) CORRELATED WITH SURVIVAL OUTCOMES IN JANUS KINASE INHIBITOR (JAKI) RELAPSED OR REFRACTORY (R/R) MYELOFIBROSIS (MF) PATIENTS (PTS)

EHA Library, Pankit Vachhani, 387914

CD47/PD-L1 BISPECIFIC ANTIBODY (IBI322) IN ANTI-PD-1 OR PD-L1 TREATMENT-RESISTANT CLASSICAL HODGKIN LYMPHOMA: A PHASE I STUDY

EHA Library, Jingwei Yu, 387916

POST-TRANSPLANT NIVOLUMAB PLUS UNSELECTED AUTOLOGOUS LYMPHOCYTES IN REFRACTORY HODGKIN LYMPHOMA RESULTS IN VERY HIGH REMISSION RATE AND EXCELLENT SURVIVAL AND IT IS ASSOCIATED WITH NK CELL EXPANSION

EHA Library, Fabio Guolo, 387917

CORRELATION BETWEEN PROGRESSION-FREE AND OVERALL SURVIVAL IN PATIENTS WITH CLASSICAL HODGKIN LYMPHOMA: A COMPREHENSIVE ANALYSIS OF INDIVIDUAL PATIENT DATA FROM RANDOMIZED GHSG TRIALS

EHA Library, Bastian von Tresckow, 387918

PREDICTING THROMBOTIC RISK IN PATIENTS WITH HODGKIN LYMPHOMA: A MULTICENTRIC STUDY OF THROLY AND KHORANA RISK SCORES

EHA Library, Ilaria Del Giudice, 387919

REAL-WORLD OUTCOMES OF BREXUCABTAGENE AUTOLEUCEL (BREXU-CEL) FOR RELAPSED OR REFRACTORY MANTLE CELL LYMPHOMA: A CIBMTR SUBGROUP ANALYSIS BY PRIOR TREATMENT

EHA Library, Nausheen Ahmed, 387920

LONG-TERM RESULTS OF THE FIL MCL0208 TRIAL COMPARING LENALIDOMIDE MAINTENANCE (LEN) VS OBSERVATION (OBS) AFTER AUTOLOGOUS STEM CELL TRANSPLANTATION (ASCT) IN MANTLE CELL LYMPHOMA (MCL)

EHA Library, Marco Ladetto, 387921

EPCORITAMAB WITH RITUXIMAB + LENALIDOMIDE (R2) PROVIDES DURABLE RESPONSES IN PATIENTS WITH HIGH-RISK FOLLICULAR LYMPHOMA, REGARDLESS OF POD24 STATUS

EHA Library, Anna Sureda Balari, 387922

REAL-WORLD EARLY OUTCOMES OF AXICABTAGENE CILOLEUCEL FOR RELAPSED OR REFRACTORY FOLLICULAR LYMPHOMA

EHA Library, Caron Jacobson, 387923

IBRUTINIB VERSUS PLACEBO IN PATIENTS WITH ASYMPTOMATIC, TREATMENT-NAÏVE EARLY STAGE CHRONIC LYMPHOCYTIC LEUKEMIA (CLL): FINAL RESULTS OF THE PHASE 3, DOUBLE-BLIND, PLACEBO-CONTROLLED CLL12 TRIAL

EHA Library, Petra Langerbeins, 387900

ALLOGENEIC STEM CELL TRANSPLANTATION FOR NK/T-CELL LYMPHOMA IN THE ERA OF ASPARAGINASE-BASED CHEMOTHERAPY: A RETROSPECTIVE ANALYSIS OF THE EBMT LYMPHOMA WORKING PARTY

EHA Library, Philipp Berning, 387925

EFFICACY OF ANTI-PD1 THERAPY  IN RELAPSED OR REFRACTORY EXTRANODAL NK/T CELL LYMPHOMA: A MATCHED COHORT ANALYSIS FROM THE LYSA

EHA Library, Amira Marouf, 387926

INITIAL SAFETY DATA FROM THE PHASE 3 POLAR BEAR TRIAL IN ELDERLY OR FRAIL PATIENTS WITH DIFFUSE LARGE CELL LYMPHOMA, COMPARING R-POLA-MINI-CHP AND R-MINI-CHOP

EHA Library, Sirpa Leppä, 387927

POSITRON EMISSION TOMOGRAPHY EVALUATION IN A LARGE GROUP OF PATIENTS AFFECTED BY RELAPSED/REFRACTORY B-CELL LYMPHOMAS TREATED WITH ANTI-19 CHIMERIC ANTIGEN RECEPTOR (CAR) T-CELLS THERAPY (CART SIE).

EHA Library, Anna Dodero, 387928

PROPHYLACTIC EFFICACY OF INTRATHECAL VERSUS INTRAVENOUS METHOTREXATE FOR CNS RELAPSE IN HIGH-RISK DIFFUSE LARGE B CELL LYMPHOMA : A PHASE III RANDOMIZED, CONTROLLED STUDY

EHA Library, Seung-Ah Yahng, 387929

CD22 CAR T CELL THERAPY IS SAFE AND EFFECTIVE IN PATIENTS WITH LARGE B CELL LYMPHOMA WHO HAVE RELAPSED AFTER CD19 CAR T CELL THERAPY.

EHA Library, Matthew J. Frank, 387930

JUVENILE MYELOMONOCYTIC LEUKEMIA (JMML) INHIBITS T CELL PROLIFERATION VIA THE ECTONUCLEOTIDASE CD39 AND THE PURINERGIC NETWORK

EHA Library, Jovana Rajak, 385450

EFFICACY AND TOXICITY OF CAR-T CELLS IN PRIMARY CENTRAL NERVOUS SYSTEM LYMPHOMAS, A NEW REFERENCE: THE FRENCH EXPERIENCE OF THE NATIONAL LOC NETWORK

EHA Library, Sylvain Choquet, 387932

AXICABTAGENE CILOLEUCEL AS SECOND-LINE THERAPY FOR LARGE B-CELL LYMPHOMA IN TRANSPLANT-INELIGIBLE PATIENTS: FINAL ANALYSIS OF ALYCANTE, A PHASE 2 LYSA STUDY

EHA Library, Roch Houot, 387933

UPDATED CLINICAL RESULTS OF FIRST-IN-HUMAN STUDY OF CD19/BCMA DUAL-TARGETING FAST CAR-T GC012F FOR PATIENTS WITH RELAPSED/REFRACTORY B-CELL NON-HODGKIN’S LYMPHOMA

EHA Library, Yi Zhang, 387934

GENERATION AND APPLICATION OF A LIVING T-CELL LYMPHOMA PATIENT-DERIVED TUMOR XENOGRAFT BIOREPOSITORY

EHA Library, Luca Vincenzo Cappelli, 387935

HIGH-BREADTH SEQUENCING OF CIRCULATING TUMOR DNA IDENTIFIES NOVEL CLASSIFICATION OF HODGKIN LYMPHOMA

EHA Library, Julia Mattlener, 387936

THE GENETIC SUBTYPES AND THE TUMOR MICROENVIRONMENT SIGNATURES ARE ASSOCIATED WITH DISTINCT OUTCOMES IN PERIPHERAL T-CELL LYMPHOMA

EHA Library, Yasuhito Suehara, 387937

CLONAL ARCHITECTURE OF RELAPSED OR REFRACTORY ANGIOIMMUNOBLASTIC T-CELL LYMPHOMA: AN ANCILLARY STUDY OF THE ORACLE TRIAL, A LYSA STUDY

EHA Library, Ivan SLOMA, 387938

SOX11 DRIVES B1A LINEAGE COMMITMENT AND B1A/MCL-LIKE LYMPHOMA FORMATION IN MICE

EHA Library, Tim Pieters, 387939

TARGETING PRMT1 ALLEVIATES CHRONIC GRAFT-VERSUS-HOST DISEASE BY REDUCING T AND B PATHOGENICITY

EHA Library, Xiaoyan Zhao, 387940

ITACONATE INHIBITS TH1 DIFFERENTIATION AND ACUTE GRAFT-VERSUS-HOST DISEASE VIA NRF2

EHA Library, Yaoyao Shen, 387941

MAST CELLS ARE MEDIATORS OF INFLAMMATORY EFFECTOR CELL RECRUITMENT AND FIBROSIS IN DERMAL CHRONIC GRAFT-VERSUS-HOST DISEASE

EHA Library, Gerhard Hildebrandt, 387942

LACTATE PRODUCED BY T CELLS DURING AGVHD PROMOTES SECOND SIGNAL GENERATION FOR T CELL ACTIVATION THROUGH HISTONE MODIFICATION

EHA Library, Hengwei Wu, 387943

OUTCOME OF FAMILIAL HEMOPHAGOCYTIC LYMPHOHISTIOCYTOSIS: REPORT ON 148 PATIENTS FROM THE ITALIAN REGISTRY

EHA Library, Francesco Pegoraro, 387944

RUXOLITINIB IN PEDIATRIC PATIENTS WITH TREATMENT-NAIVE OR STEROID-REFRACTORY CHRONIC GRAFT VERSUS HOST DISEASE: PRIMARY FINDINGS FROM THE PHASE II REACH5 STUDY

EHA Library, Franco Locatelli, 387945

JAK/ROCK INHIBITOR TQ05105 FOR GLUCOCORTICOID-REFRACTORY OR -DEPENDENT CHRONIC GRAFT-VERSUS-HOST DISEASE：UPDATED RESULTS OF A PHASE 1B/2 STUDY

EHA Library, He Huang, 387946

ADDING RUXOLITINIB AND DECITABINE TO BU/CY CONDITIONING REGIMENS TO PROPHYLAXIS POST-TRANSPLANT RELAPSE IN HIGH-RISK AML IS SAFE AND EFFECTIVE: A PROSPECTIVE, PHASE Ⅱ STUDY

EHA Library, Dai-Hong Liu, 387947

SIERRA TRIAL RESULTS WITH A TARGETED RADIOTHERAPY, IOMAB-B, A MYELOABLATIVE CONDITIONING WITH REDUCED INTENSITY TOLERABILITY YIELDS HIGH CR, LONG TERM SURVIVAL IN HSCT INELIGIBLE ACTIVE R/R AML

EHA Library, Boglarka Gyurkocza, 387948

SELECTIVE JAK2/IRAK1/ACVR1 INHIBITOR PACRITINIB BEFORE REDUCED-INTENSITY CONDITIONING ALLOGENEIC STEM CELL TRANSPLANTATION IN MYELOFIBROSIS: FINAL ANALYSIS OF THE PHASE II HOVON-134 TRIAL

EHA Library, Ruben Van Dijck, 387949

UNVEILING THE BIOLOGICAL ROLE OF PERIPHERAL BLOOD HUMAN CIRCULATING HEMATOPOIETIC STEM AND PROGENITOR CELLS

EHA Library, Scala Serena, 387950

P-SELECTIN CONTRIBUTES TO HEMATOPOIETIC STEM CELLS AGING BY SENSING THE NICHE

EHA Library, Daozheng Yang, 387951

MODULATING HEMATOPOIESIS: ENGINEERING TPO VARIANTS WITH DISTINCT HEMATOPOIETIC FUNCTION

EHA Library, Zahra Masoumi, 387952

IMPAIRED HSC FITNESS AND ACCELERATED LEUKEMOGENESIS IN A MOUSE MODEL OF CHRONIC INFLAMMATION

EHA Library, Srdjan Grusanovic, 387953

A NEW GENE AHED PLAYS ESSENTIAL ROLES IN HEMATOPOIESIS THROUGH RNA-SPLICING

EHA Library, Ritsuko Nakai, 387954

CELLULAR SENESCENCE AND INFLAMMATORY PROGRAMS ARE UNINTENDED CONSEQUENCES OF CRISPR-CAS9 GENE EDITING IN HEMATOPOIETIC STEM AND PROGENITOR CELLS

EHA Library, Anastasia Conti, 387955

HLA-E/NKG2A CHECKPOINT DRIVES MULTIPLE MYELOMA RESISTANCE TO CAR-NK THERAPY

EHA Library, Jessica Encinas, 387956

CAR T CELLS AND THEIR IMMUNE ENVIRONMENT SHAPE DISTINCT IMMUNE PROFILES IN RESPONSE AND TOXICITY IN B CELL LYMPHOMA PATIENTS

EHA Library, Stefanie Kreutmair, 387957

IPH6501 IS A FIRST-IN-CLASS TETRASPECIFIC ANTIBODY-BASED NATURAL KILLER CELL ENGAGER THERAPEUTIC DEVELOPED FOR THE TREATMENT OF B-CELL NON-HODGKIN'S LYMPHOMAS

EHA Library, Olivier Demaria, 387958

SAR444245, A NON-ALPHA IL2, RESCUES CHRONIC ANTIGEN- AND CAR-DRIVEN T-CELL DYSFUNCTION

EHA Library, Patrick Reville, 387959

IMMUNE EFFECTOR CELL ASSOCIATED HEMATOTOXICITY (ICAHT) FOLLOWING CAR T-CELL THERAPY: INTERNATIONAL SURVEY AND CONSENSUS GUIDELINES ON ITS GRADING, DIAGNOSIS, AND MANAGEMENT ON BEHALF OF EHA AND EBMT

EHA Library, Kai Rejeski, 387960

FIRST IN HUMAN DATA OF NKX019, AN ALLOGENEIC CAR NK FOR THE TREATMENT OF RELAPSED/REFRACTORY (R/R) B-CELL MALIGNANCIES

EHA Library, Michael Dickinson, 387961

SAFETY AND EFFICACY OF OBECABTAGENE AUTOLEUCEL (OBE-CEL), A FAST-OFF RATE CD19 CAR IN RELAPSED/REFRACTORY ADULT B-CELL ACUTE LYMPHOBLASTIC LEUKAEMIA:TOP LINE RESULTS OF THE PIVOTAL FELIX STUDY

EHA Library, Claire Roddie, 387962

CYTOPENIAS, AGE AND CAR-HEMATOTOX SCORE PREDICT THE DEVELOPMENT OF POST CAR T-CELL THERAPY-RELATED MYELOID NEOPLASMS

EHA Library, Mark Gurney, 387963

EDIT-301 SHOWS PROMISING PRELIMINARY SAFETY AND EFFICACY RESULTS IN THE PHASE I/II CLINICAL TRIAL (RUBY) OF PATIENTS WITH SEVERE SICKLE CELL DISEASE USING HIGHLY SPECIFIC AND EFFICIENT ASCAS12A ENZYME

EHA Library, Rabi Hanna, 387964

MATERNAL AND PERINATAL OUTCOMES OF SICKLE CELL DISEASE IN PREGNANCY: A NATIONWIDE STUDY IN FRANCE.

EHA Library, Laure Joseph, 387965

DIFFERENT MOLECULAR VASO-OCCLUSIVE TRIGGERS STIMULATE DISTINCT VASO-OCCLUSIVE PROFILES: IN VIVO RESULTS FROM MICE WITH SICKLE CELL ANEMIA

EHA Library, Lucas F. S. Gushiken, 387966

PHARMACOKINETICS/PHARMACODYNAMICS, SAFETY AND EFFICACY OF CRIZANLIZUMAB IN PATIENTS WITH SICKLE CELL DISEASE AGED 12 TO <18 YEARS: 2-YEAR DATA FROM THE PHASE 2 SOLACE-KIDS STUDY

EHA Library, Matthew Heeney, 387967

INTERIM ANALYSIS OF A PHASE 2 TRIAL TO ASSESS THE EFFICACY AND SAFETY OF CRIZANLIZUMAB IN SICKLE CELL DISEASE PATIENTS WITH PRIAPISM (SPARTAN)

EHA Library, Alan Anderson, 387968

MALE PATIENTS WITH SCD HAVE A HIGHER RISK OF CEREBROVASCULAR DISEASE, INCREASED INFLAMMATORY MARKERS, AND POORER RESPONSE TO HYDROXYUREA

EHA Library, Margherita Di Mauro, 387969

TRANSFUSION INDEPENDENCE AFTER EXAGAMGLOGENE AUTOTEMCEL IN PATIENTS WITH TRANSFUSION-DEPENDENT ΒETA-THALASSEMIA

EHA Library, Franco Locatelli, 387970

AN UPDATED FOLLOW-UP OF BRL-101, CRISPR-CAS9-MEDIATED GENE EDITING OF THE BCL11A ENHANCER FOR TRANSFUSION-DEPENDENT BETA-THALASSE

EHA Library, Biao Zheng, 387971

SAFETY AND EFFICACY OF RM-001 IN PATIENTS WITH TRANSFUSION-DEPENDENT Β-THALASSEMIA: EARLY RESULTS FROM THE ONGOING OF AUTOLOGOUS HBG1/2 PROMOTER-MODIFIED CD34+ HEMATOPOIETIC STEM AND PROGENITOR CELLS

EHA Library, Rongrong Liu, 387972

LONG-TERM ERYTHROID RESPONSE DATA FROM PATIENTS (PTS) WITH NON-TRANSFUSION-DEPENDENT ΒETA-THALASSEMIA (NTDT) RECEIVING LUSPATERCEPT IN THE BEYOND TRIAL

EHA Library, Ali T. Taher, 387973

A NEW, EFFECTIVE, SAFE, NON-MYELOABLATIVE CONDITIONING REGIMEN WITH A HLA-MATCHED SIBLING DONOR FOR THE SEVERE SICKLE CELL PHENOTYPE IN ADULTS

EHA Library, Laure Joseph, 387974

PUS1 REGULATES ERYTHROPOIESIS VIA TRNA PSEUDOURIDYLATION AND CYTOPLASMIC TRANSLATION

EHA Library, Yajing Chu, 387975

POVETACICEPT (ALPN-303), A POTENT DUAL BAFF/APRIL ANTAGONIST, FOR THE TREATMENT OF AUTOIMMUNE CYTOPENIAS AND OTHER ANTIBODY-RELATED DISEASES

EHA Library, Stacey Dillon, 387976

IPSC DISEASE MODELS TO STUDY AND TREAT DIAMOND-BLACKFAN ANEMIA SYNDROME (DBAS)

EHA Library, Marije Bartels, 387977

CEREBRAL HEMODYNAMICS AND OXYGEN METABOLISM IN PATIENTS WITH MILD AND SEVERE SICKLE CELL DISEASE AND THALASSEMIA

EHA Library, Liza Afzali-Hashemi, 387978

EFFECT OF VOXELOTOR ON CEREBRAL PERFUSION AND CEREBRAL OXYGEN METABOLISM IN ADULT PATIENTS WITH SICKLE CELL DISEASE; THE COVERAGE STUDY

EHA Library, Kadère Konté, 387979

PRIMARY MEDIASTINAL B-CELL LYMPHOMA HAVE A SUPERIOR OUTCOME COMPARED TO DIFFUSE LARGE-B-CELL LYMPHOMA TREATED WITH AXICABTAGENE CILOLEUCEL IN THE CART-SIE REAL LIFE ITALIAN STUDY

EHA Library, Annalisa Chiappella, 387931